Dermata Therapeutics Inc Stock Price, News & Analysis

Dermata Therapeutics (NASDAQ:DRMA / DRMAW) announced a private placement to issue 2,022,062 shares (or pre-funded warrants) plus series C and short-term series D warrants at $2.04 per share, providing approximately $4.1 million of gross proceeds upfront and up to ~$8.3 million additional if warrants are fully exercised (total ~$12.4 million). Series C warrants expire five years; series D warrants expire 24 months; warrant exercises and amended warrants are subject to stockholder approval. Closing expected on or about December 29, 2025. Company insiders, including the CEO and CFO, are participating. H.C. Wainwright is placement agent. Net proceeds for general corporate purposes and OTC acne kit activities.

Dermata Therapeutics (NASDAQ:DRMA) announced it will unveil a new brand identity for its over-the-counter skincare business in the coming weeks, positioning the unit as a "science-first" consumer skincare brand that blends ancestral remedies with clinical innovation. The company said the identity reflects a mission to deliver potent, health-forward products and will frame therapies and technologies through quantifiable performance.

Dermata plans to launch its first OTC once-weekly acne kit in mid-2026 and will release visual assets, product positioning, and phased launch communications over the coming months.

Dermata Therapeutics (Nasdaq: DRMA) announced a strategic pivot to develop and commercialize over-the-counter dermatology products and reported Q3 2025 results. The company plans to launch a once-weekly acne kit using its Spongilla technology in mid-2026 and is developing branding, packaging, and manufacturing for direct-to-consumer and professional sales.

Recent clinical progress includes positive topline Phase 3 STAR-1 results that met all three primary endpoints and showed separation from placebo by week 4. As of September 30, 2025, Dermata had $4.7 million in cash and expects funding into Q2 2026.

Dermata Therapeutics (NASDAQ:DRMA) announced the acceptance of its patent application by the Australian Patent Office for its Spongilla technology combination to treat acne. The patent, which follows a similar U.S. patent issuance, will automatically be granted in mid-January 2026 unless opposed.

The company plans to launch a once-weekly, Over-the-Counter (OTC) pharmaceutical acne kit incorporating its Spongilla technology by mid-2026. This innovative treatment targets underlying acne mechanisms with enhanced precision, potentially offering improved outcomes and reduced side effects. The Australian market represents a significant opportunity with over 3.3 million people diagnosed with acne.

Dermata Therapeutics (NASDAQ:DRMA) announced the upcoming presentation of an abstract from its Phase 3 STAR-1 clinical trial of XYNGARI™ (DMT310) at the European Academy of Dermatology and Venereology Congress 2025 in Paris, France.

The abstract, titled "Once Weekly Topical Treatment with DMT310 Demonstrates Significant and Early Onset of Effect in Patients with Moderate to Severe Acne Vulgaris," will be released on September 16, 2025. The presentation will highlight additional primary and secondary data from the Phase 3 study evaluating XYNGARI™ for moderate-to-severe acne treatment.

Dermata Therapeutics (Nasdaq:DRMA) announced a strategic pivot from prescription medications to over-the-counter (OTC) skin care treatments. This decision follows the successful Phase 3 STAR-1 clinical trial of XYNGARI™, their once-weekly topical acne treatment using proprietary Spongilla technology.

The company plans to launch its first OTC acne kit by mid-2026, targeting nearly 50 million US acne patients. The product will combine an FDA-approved OTC monograph active ingredient with their Spongilla technology. This strategic shift aims to accelerate commercialization, reduce regulatory burden, and broaden customer access by eliminating insurance coverage limitations.

As part of this transition, Dermata has withdrawn its investigational new drug application for XYNGARI™ with the FDA to gain more flexibility in leveraging its Spongilla technology for various OTC skin care products.

Dermata Therapeutics (NASDAQ:DRMA) reported significant progress in Q2 2025, highlighted by positive Phase 3 STAR-1 trial results for XYNGARI™ in treating moderate-to-severe acne. The trial achieved statistically significant results for all three co-primary endpoints at both 4 and 12 weeks versus placebo.

The company strengthened its financial position by raising $8.8 million in gross proceeds through private placement and warrant inducement financings in H1 2025. As of June 30, 2025, Dermata had $6.5 million in cash, expected to fund operations into Q2 2026. Q2 R&D expenses decreased to $0.6 million from $2.0 million year-over-year, while G&A expenses increased to $1.2 million from $0.9 million.

Dermata Therapeutics (NASDAQ:DRMA) has received a patent grant from the Australian Patent Office for its DMT410 program, which uses Spongilla technology to topically deliver botulinum toxin for treating hyperhidrosis. This marks the company's second granted patent for DMT410.

The patent, titled "Compositions for the treatment of skin conditions" (No. 2109284621), strengthens Dermata's global intellectual property portfolio. The company has recently entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 specifically for axillary hyperhidrosis treatment, with potential applications for palmer and plantar hyperhidrosis.

Dermata Therapeutics (NASDAQ: DRMA) reported significant progress in Q1 2025, highlighted by positive topline results from its XYNGARI™ Phase 3 STAR-1 clinical trial for moderate-to-severe acne treatment. The trial achieved all three co-primary endpoints with statistical significance versus placebo, showing efficacy after just 4 weeks. The company also entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 with DAXXIFY® for axillary hyperhidrosis treatment.

Financially, Dermata raised $8.8 million in gross proceeds during Q1 2025, ending the quarter with $9.7 million in cash. R&D expenses decreased to $1.3 million from $1.6 million year-over-year, while G&A expenses reduced to $1.1 million from $1.6 million. The company expects current cash resources to fund operations into Q1 2026.